Source: Pluristem Therapeutics, Inc.
Posted: November 27, 2007 8:43 am ET
Summary:
Pluristem Therapeutics, Inc., a leading bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and autoimmune disorders, announced today that in vitro testing of its PLacenta eXpanded (PLX) cells demonstrated the potential to treat autoimmune disorders.
